


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-2.38%
+0.19%
+1.99%
+1.01%
+2.83%
NVS
Novartis AG
$141.68
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
NVS Price Performance
$132.57 (+6.87%)
$129.97 (+9.01%)
$125.02 (+13.33%)
$101.84 (+39.12%)
NVS has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

NVS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Reported a weak earnings

Income increase YoY

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
NVS Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
NVS Street Sentiment is bullish and have positive views on the near-term outlook
Average key support and resistance price levels
PFE
25.15
-0.49%
AZN
94.51
+0.94%
SNY
47.20
-0.84%
MRK
108.26
-0.88%
REGN
758.91
-1.18%
NVS
Novartis AG
141.68
-0.10%
INDV
Indivior PLC
34.00
-1.62%
BAH
Booz Allen Hamilton
95.33
-1.49%
PLAB
Photronics Comm
33.39
-0.92%
FAT
FAT Brands
0.39
-1.53%
What is NVS current stock price?
What are NVS stock strengths?
What is NVS Risk Level?
What is NVS market cap and volume?
What is NVS current Stock IQ?
Should I buy NVS stock right now?
Is NVS a Strong Buy right now?
What does a 'Strong Buy' rating mean for NVS?
What does a 'Strong Sell' rating mean for NVS?
What factors influence NVS's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.38%
+0.19%
+1.99%
+1.01%
+2.83%
NVS
Novartis AG
Current Price
$141.68
NVS Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
Linked to NVS
PFE
25.15
-0.49%
AZN
94.51
+0.94%
SNY
47.20
-0.84%
MRK
108.26
-0.88%
REGN
758.91
-1.18%
Recently Viewed
NVS
Novartis AG
141.68
-0.10%
INDV
Indivior PLC
34.00
-1.62%
BAH
Booz Allen Hamilton
95.33
-1.49%
PLAB
Photronics Comm
33.39
-0.92%
FAT
FAT Brands
0.39
-1.53%

NVS Price Performance
$132.57 (+6.87%)
$129.97 (+9.01%)
$125.02 (+13.33%)
$101.84 (+39.12%)
NVS Analysts Opinion
NVS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Reported a weak earnings

Income increase YoY

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
NVS Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
NVS Street Sentiment is bullish and have positive views on the near-term outlook
NVS has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
NVS Latest Analysis
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Mon Jan 12, 2026
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow.
Mon Jan 12, 2026
Is Novartis AG Gaining or Losing Market Support?. NVS) short interest as a percent of float has risen 7.69% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will ...
Mon Jan 12, 2026
SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimers Disease. ROCKVILLE Md. SciNeuro grants Novartis an exclusive worldwide license to develop SciNeuro'.s novel antibody program that leverages a proprietary shuttle technology to enhance brain delivery of therapeutic agents to treat Alzheimer'.s DiseaseSciNeuro and Novartis will collaborate during early development with Novartis leading subsequent development and c
Mon Jan 12, 2026
Barclays Upgrades Novartis AG - Depositary Receipt (NVS). Fintel reports that on January 6 2026 Barclays upgraded their outlook for Novartis AG - Depositary Receipt (NYSE:NVS) from Underweight to Equal-Weight. Analyst Price Forecast Suggests 5.08% Downside
Wed Jan 7, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.